Overview
This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis.
Description
This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis. Using patient-completed questionnaires, combined with outpatient visit records and telephone follow-up, this study will explore the following aspects:
Assess the incidence and severity of cancer-related fatigue in patients with malignant tumors.
Analyze the influencing factors of cancer-related fatigue, including tumor type, treatment regimen, disease stage, efficacy of anti-tumor therapy, adverse events associated with anti-tumor therapy, and concomitant medications.
Evaluate the impact of cancer-related fatigue on anti-tumor treatment and prognosis.
Assess the multidimensional state and severity of cancer-related fatigue in patients with malignant tumors using the Brief Fatigue Inventory - Cancer (BFI-C) and the Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF).
By collecting patients' medical information, including imaging and laboratory results, as well as outpatient and telephone follow-up records, this study will explore the following aspects:
Evaluate the impact of different degrees of cancer-related fatigue on the prognosis of patients with malignant tumors.
Explore the impact of the efficacy of anti-tumor therapy on the multidimensional state and severity of cancer-related fatigue in patients.
Eligibility
Inclusion Criteria:
- Male or female, aged 18 years or older.
- Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form.
- Malignant tumor confirmed histologically or cytologically.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Patients with acute or chronic infections, or those with other serious medical conditions that, in the investigator's judgment, make them unsuitable for this study.
- Patients with two or more concurrent malignant tumors (excluding the following: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma).
- Patients with psychiatric illness or mental disorders, poor compliance, or who are unable to cooperate and report treatment responses.
- Patients with severe organic disease or major organ failure, such as decompensated heart, lung, liver, or kidney failure.
- Patients with other conditions that, in the investigator's opinion, make them unsuitable for participation in this study.
